Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Generalized aminoaciduria, uricosuria, glycosuria and phosphaturia were discovered in a patient with advanced Burkitt's lymphoma with renal infiltration. The literature is reviewed and three pathogenetic mechanisms are discussed. It is presumed that proximal tubular dysfunction in this case was related to the marked peritubular infiltrate causing cell mediated immunological injury or direct tubular destruction by tumor.
 ...
PMID:Proximal tubulare dysfunction associated with Burkitt's lymphoma. 63 May 39

Fourteen patients with American Burkitt's lymphoma resistant to conventional chemotherapy were treated with high-dose combination chemotherapy and intensive supportive care. Four patients died shortly after chemotherapy, 3 of an acute carditis. All ten remaining patients demonstrated tumor regression and 3 remain in prolonged complete unmaintained remission 29+, 19+, and 9+ months after treatment. These findings demonstrate that high-dose chemotherapy will benefit some patients with Burkitt's lymphoma unresponsive to conventional chemotherapy, but the medullary and extramedullary toxicity of this treatment strategy remains a formidable obstacle.
 ...
PMID:Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. 63 47

An uncommon primary site for an American Burkitt's lymphoma in the nasopharyngeal region was demonstrated by radiogallium imaging in a 14-year-old white boy. Fifth cranial nerve involvement and cerebrospinal fluid cytology for Burkitt's responded initially to four drug chemotherapy with objective reduction in the tumor radiogallium uptake. Clinical relapse and recurrence of the tumor radiogallium uptake in less than three weeks following the completion of therapy was observed. Local irradiation and chemotherapy successfully reduced the symptoms and eliminated the radiogallium tumor uptake. Radiogallium imaging is advocated as a principal method for staging and monitoring the course of Burkitt's lymphoma.
 ...
PMID:The role of 67Ga in an unusual form of American Burkitt's lymphoma. 65 76

The clinical doubling times of human solid tumors are reviewed. Methods are also described for estimating subclinical tumor doubling times, and these methods are applied to Wilms' tumor, choriocarcinoma, Burkitt's tumor, and breast cancer. Rapidly growing tumors are often responsive to therapy, and such complete responses are often quite durable. Slowly growing tumors respond less favorably to therapy, and responses are generally not durable. Rapidly growing tumors in advanced stages are similar in their response behavior to the slowly growing tumors. A strategy based on cell kinetics principles and tumor doubling time data is proposed for improving therapeutic results in responsive tumors. Data on clinical and subclinical tumor doubling times are used to distinguish early recurrences from late recurrences in a given tumor type. Early recurrences call for intensification of induction therapy, whereas late recurrences call for prolongation of consolidative therapy. This strategy may also apply in adjuvant therapy of slowly growing tumors.
 ...
PMID:Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. 66 55

If the study of tumor immunology is to have a profound impact on clinical medicine, certain hypotheses must be proven to be valid. First and foremost, it must be demonstrated that malignant tissue possesses antigenic substances (probably protein moieties) that are unique to that particular malignant process. In addition, these antigenic substances must be very similar in histologically similar tumors. Second, the host defense mechanisms must be capable of reacting to these tumor-associated antigens. The reaction is, of course, necessary in order to develop both diagnostic and therapeutic routes of application. The reaction of the immunologic system to these tumor-associated antigens could be monitored as an early serodiagnostic tool for subclinical cancer, and the cytotoxic reaction holds great promise as an immunotherapeutic tool. The essence of tumor immunologic research can thus be stated in the form of the following questions: 1. Do histologically similar cancers from identical primary sites share common tumor-associated antigens? 2. Does the immunologic system react to these antigens? 3. Can this reaction be assayed on one hand for serodiagnosis and augmented on the other for immunotherapy? Specific antigens have been found in animal tumors and have been divided into two classes: the viral induced tumors, which share common antigens when caused by the same viral agent, and carcinogen-induced tumors, which appear to have unique antigenic determinants for each tumor. In recent years a great many human tumors have been found to have tumor-associated antigens; these include colonic carcinoma, neuroblastoma, melanoma, soft tissue and osteogenic sarcoma, bladder carcinoma and Burkitt's lymphoma. This report includes evidence for the existence of such antigens in adenocarcinoma of the ovary and squamous cell carcinoma of the cervix. The laboratory evidence that has been presented would suggest that there are both a cell-mediated response and humoral response to the antigenic determinants of these two gynecologic cancers. It would appear that the mediated (lymphocyte) effect is considerably more cytotoxic and definitive than the humoral factors measured. In addition, the allogenic experiments would suggest strongly that indeed (at least with regard to these two cancers) histologically similar cancers from the same organ share common antigenic determinants. The identification and isolation of these tumor-associated antigens appears complex. The complexity is increased when one studies patients afflicted with these cancers for plasma carcinoembryonic antigens. This antigen, which was thought to be specific for adenocarcinoma of the colon, is found in the blood of a significant number of patients with adenocarcinoma of the ovary and squamous cell carcinoma of the cervix.
 ...
PMID:Tumor-associated antigens in gynecologic cancer. 76 38

A randomized clinical trial designed to compare the effectiveness of cytoxan (CTX) alone versus a combination consisting of CTX, vincristine (Oncovin) and methotrexate (COM) in the treatment of Burkitt's lymphoma (BL) was carried out. Nineteen patients were selected at random to receive CTX alone while 21 received COM. The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for CTX- and COM-treated patients, respectively. The relapse frequencies were also equal but the pattern of relapse was clearly different. Seven out of 8 (87.5%) in the CTX group relapsed with systemic and central nervous system (CNS) tumor, while 8 out of 10 (80%) in the COM group relapsed with CNS disease only. This difference is highly significant p = 0.008. The remission durations and survival to date are the same.
 ...
PMID:Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. 77 40

Two established North American Burkitt lymphoma cell lines were studied by chromosomal banding techniques. The SU-AmB-1 line previously shown to be negative for the Epstein-Barr virus (EBV) was found to have, among other changes, a translocation from the long arm (q) of chromosome 8 onto 14q. The SU-AmB-2 line, which contains the EBV genome, also displayed the same 8/14 translocation. These results were compared with data from three EBV-positive tumor cell lines derived from patients with African Burkitt's lymphoma. Our findings indicate that a translocation from 8q onto 14q occurs in both African and North American Burkitt lymphomas, and that this abnormality apparently is not related directly to EBV. This chromosome translocation therefore may be an important event in the development of human lymphocytic malignancy, analogous to the occurrence of the Philadelphia chromosome rearrangement in chronic myelogenous leukemia.
 ...
PMID:Chromosome 14 translocation in African and North American Burkitt's lymphoma;. 84 16

The chromosomal aberrations in tumor cells obtained by bone marrow aspiration from a patient with non-endemic Burkitt's lymphoma (BL) are reported. Twenty percent of the cells contained the marker chromosome 14q+ earlier described in endemic Burkitt's tumors. Other marker chromosomes were dound only in mitoses which did not contain the 14q+.
 ...
PMID:Marker chromosome 14q+ in non-endemic Burkitt's lymphoma. 85 42

A retrospective study was conducted on 127 patients with Burkitt's lymphoma who had partial or complete records of both clinical and pathologic features of their disease. An analysis and description of the anatomical tumor distribution based on post-mortem examinations was made, highlighting lack of correlation between clinical staging and pathologic findings. A consistent observation was the high incidence of involvement of the kidney, liver, and heart in each of the stages (I-III).The data to be presented will clarify at least in part, the unpredictability of response of Burkitt's lymphoma patients to chemotherapeutic agents, because total cell-kill, needed for cure and/or prevention of relapse, is made almost impossible due to the widespread tumor volume carried by the patients.Effective supportive treatment might be a life-saving adjuvant regimen in treatment of Burkitt's lymphoma patients, where the organs so commonly involved might fail to function.
 ...
PMID:Pattern of organ involvement in Burkitt's lymphoma in Ibadan: a review. 86 71

Burkitt's lymphoma in Africa may be curable by chemotherapy alone; in nonendemic regions results are reportedly less favorable. Fifty-four Americans with Burkitt's lymphoma were treated with two sequential combined treatment regimens that incorporated therapeutic approaches from clinical trials in Africa. Four patients died during induction therapy, and 48 of the remaining 50 achieved complete remissions. Twenty-two relapsed at a median of three months from the start of therapy. The overall two-year actuarial survival was 54 percent: younger patients ( less than 12 years old) and patients with minimal tumor burden (stages A, B and AR) had significantly better survivals than older patients (P less than 0.02) and patients with advanced abdominal tumors (stages C and D) (P less than 0.01). No differences in survival were detected between patients treated at the National Institutes of Health and those treated in regional institutions on either protocol. Complete response rates, relapse frequency and survival in American patients are similar to results in Africa.
 ...
PMID:Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. 86 79


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>